Document is current
Any future updates will be listed below
-
Authors
Xiao, Shifu https://orcid.org/0000-0002-4721-9646
Chan, Piu
Wang, Tao
Hong, Zhen
Wang, Shuzhen
Kuang, Weihong
He, Jincai
Pan, Xiaoping
Zhou, Yuying
Ji, Yong
Wang, Luning
Cheng, Yan
Peng, Ying
Ye, Qinyong
Wang, Xiaoping
Wu, Yuncheng
Qu, Qiumin
Chen, Shengdi
Li, Shuhua
Chen, Wei
Xu, Jun
Peng, Dantao
Zhao, Zhongxin
Li, Yansheng
Zhang, Junjian
Du, Yifeng
Chen, Weixian
Fan, Dongsheng
Yan, Yong
Liu, Xiaowei
Zhang, Wei
Luo, Benyan
Wu, Wenyuan
Shen, Lu
Liu, Chunfeng
Mao, Peixian
Wang, Qiumei
Zhao, Qianhua
Guo, Qihao
Zhou, Yongtao
Li, Yi
Jiang, Lijun
Ren, Wenwei
Ouyang, Yingjun
Wang, Yan
Liu, Shuai
Jia, Jianjun
Zhang, Nan
Liu, Zhonglin
He, Raoli
Feng, Tingyi
Lu, Wenhui
Tang, Huidong
Gao, Ping
Zhang, Yingchun
Chen, Lanlan
Wang, Lei
Yin, You
Xu, Qun
Xiao, Jinsong
Cong, Lin
Cheng, Xi
Zhang, Hui
Gao, Dan
Xia, Minghua
Lian, Tenghong
Peng, Guoping
Zhang, Xu
Jiao, Bin
Hu, Hua
Chen, Xueyan
Guan, Yihui
Cui, Ruixue
Huang, Qiu
Xin, Xianliang
Chen, Hongjian
Ding, Yu
Zhang, Jing
Feng, Teng
Cantillon, Marc
Chen, Kewei
Cummings, Jeffrey L.
Ding, Jian
Geng, Meiyu
Zhang, Zhenxin
-
Funding
Funding for this research was provided by:
National Science and Technology Major Project for Investigational New Drugs (2011ZX09101-003-01, 2015ZX09101003, 2018ZX09711002-015)
- License Information
-
More Information
Article History
Received: 12 November 2020
Accepted: 22 February 2021
First Online: 17 March 2021
Declarations
:
: The trial protocol was approved by the Ethics Review Board of Shanghai Mental Health Center (Shanghai, China). The trial protocol was approved by the Institutional Review Boards of all participating sites. The Clinical New Drug Research and Development Team of the Department of Psychogeriatrics of Shanghai Mental Health Center and the sponsor designed the study in consultation with academic advisors. All participants or their representatives provided written informed consent before participation in the trial.
: All authors approved the final version of the manuscript for submission.
: Shifu Xiao and Zhenxin Zhang have been the provisional consultants of Pfizer, Lilly, Novartis, Roche, GSK, Johnson & Johnson, Lundbeck, Biogen, and Green Valley and received honorariums. Xianliang Xin, Hongjian Chen, Yu Ding, Jing Zhang, and Marc Cantillon were full-time employees of Shanghai Green Valley Pharmaceutical Co., Ltd. Kewei Chen was a full-time employee of Shanghai Green Valley Pharmaceutical Co., Ltd. at the time the [<sup>18</sup>F]-FDG-PET data was analyzed. Currently, he is a full-time employee of Banner Health to which Banner Alzheimer’s Institute belongs, and serves as a paid consultant to Shanghai Green Valley Pharmaceutical Co., Ltd. Jeffrey L. Cummings has provided consultation to Acadia, Actinogen, Alkahest, Alzheon, Avanir, Axsome, BiOasis Technologies, Biogen, Cerecin, CNS Innovations, Cortexyme, EIP, Eisai, Genentech, Green Valley, Grifols, Hisun, Idorsia, Merck, Otsuka, Resverlogix, Roche, Samus, Samumed, Sunovion, Suven, and United Neuroscience pharmaceutical and assessment companies.
